Optimising the therapeutic efficacy of anti-inflammatory macrophages for use in chronic kidney diseases

慢性肾脏疾病(CKD)是澳大利亚人死亡和发病的主要原因。目前能够延缓慢性肾脏病进展的治疗方法是有限的。因此，每年有超过2300名澳大利亚人需要肾脏置换，更多的人死于肾衰竭。我们已经通过给予保护性白细胞-巨噬细胞来减少和防止CKD小鼠模型的损伤。该项目将在体外对巨噬细胞进行修饰，以优化它们作为CKD的治疗方法。

Chronic kidney disease (CKD) is a major cause of death and morbidity in Australia. Current treatments that are able to delay progression for CKD are limited. As a consequence, more than 2300 additional Australians need kidney replacement each year and many more die of kidney failure. We have reduced and prevented injury in a mouse model of CKD by administering protective white blood cells - macrophages. This project will modify macrophages ex vivo to optimize them for use as a therapy for CKD.